HCMED INNOVATIONS Reaches Breakthrough Milestone with FDA Approval for Innovative Breath-Activated Nebulizer

HCMED INNOVATIONS, specializing in inhalation drug-device combination CDMO products, announced that its breath-activated nebulizer AdheResp has recently received U.S. FDA 510(k) clearance. AdheResp is the world’s first FDA-cleared breath-activated nebulizer with built-in connectivity, and currently the only advanced nebulizer device with mass production capacity to support pharmaceutical clients’ clinical trials.